

해외 바이오의약품 임상 현황 (2019.10.15~2019.10.21)

한국바이오의약품협회, 2019.10.22
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04109482	Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS.	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Acute Myeloid Leukemia Relapsed or Refractory HRMDS	Biological: MB-102 Drug: Decitabine Drug: Fludarabine Drug: Cyclophosphamide	Mustang Bio	Phase 1 Phase 2
NCT04114136	Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Melanoma Renal Cell Carcinoma NSCLC Hepatocellular Carcinoma Urothelial Cancer Gastric Adenocarcinoma HNSCC Esophageal Adenocarcinoma Microsatellite Instability-High Solid Malignant Tumor	Drug: Nivolumab or Pembrolizumab (dependent upon approved indication) Drug: Metformin Drug: Rosiglitazone	Dan Zandberg University of Pittsburgh	Phase 2
NCT04104672	A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies	Advanced Pancreatic Cancer	Drug: AB680 Drug: AB122	Arcus Biosciences, Inc.	Phase 1
NCT04059757	Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD	Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)	Biological: Fecal Microbiota Transplantation (FMT)	Leland Metheny Case Comprehensive Cancer Center	Phase 2
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03533816	Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide	Acute Myeloid Leukemia Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndromes	Drug: EAGD T-cell infusion (Phase I) Drug: EAGD T-cell infusion (Expansion)	University of Kansas Medical Center Incysus	Phase 1
NCT03271814	Brain Biomarker on Inflammation Response	Schizophrenia	Biological: LPS Other: Placebo	University of Maryland, Baltimore	Phase 1
NCT04046549	A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant	Allografts Rejection; Transplant, Kidney Transplant Rejection Kidney Transplantation	Drug: Belatacept Drug: VIB4920	Viela Bio	Phase 2
NCT03414788	Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis	Ulcerative Colitis	Biological: PF 06687234 Biological: [124I]IB PF 06687234	Pfizer	Phase 1
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

해외 바이오의약품 임상 현황 (2019.10.15~2019.10.21)

한국바이오의약품협회, 2019.10.22
출처: ClinicalTrials.gov

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04104607	the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma	Castration-Resistant Prostatic Cancer	Drug: CC-1, PSMAxCD3	University Hospital Tuebingen German Cancer Research Center	Phase 1
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3
NCT04082429	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors	Haemophilia A Without Inhibitors Haemophilia B Without Inhibitors	Drug: Concizumab	Novo Nordisk A/S	Phase 3
NCT04083781	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors	Haemophilia A With Inhibitors Haemophilia B With Inhibitors	Drug: Concizumab	Novo Nordisk A/S	Phase 3

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04123886	A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion	Malignant Pleural Effusion	Drug: SCB-313	Sichuan Clover Biopharmaceuticals, Inc.	Phase 1
NCT04065672	Low-dose IL-2 Treatment on Behcet's Disease	Behcet's Disease	Drug: Low-dose IL-2	Peking University People's Hospital	Phase 2
NCT04034615	The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars	Cicatrix	Biological: Mesenchyme Stem Cells low-dose group Biological: Mesenchyme Stem Cells high-dose group Biological: Placebo	Maternal and Child Health Hospital of Foshan	Phase 2
NCT04025931	A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma	Sarcoma	Drug: chidamide and toripalimab	Sun Yat-sen University	Phase 2